References

High sensitivity, increased specificity, and improved precision
for accurate prediction of recurrence and better stratification
patients with improved PFS over genomic-only methods1,2

Enhanced Performance

Rapid Turnaround Time

Averaging 9 days in the clinical setting to accelerate
trial enrollment and assess response sooner3,4

MRD, minimal residual disease; PFS, progression-free survival.

QUANTIFY CANCER

Guardant Infinity enables liquid-only MRD and response monitoring that is accessible and scalable across clinical trials.

Tissue-Free Sampling

A simple blood draw making it significantly easier to
acquire, enabling a higher evaluable rate for clinical studies

Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma